JH
Therapeutic Areas
Solid Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SGT-003 | Duchenne muscular dystrophy (Duchenne) | Phase 1/2 |
| SGT-212 | Friedreich’s ataxia (FA) | Not Specified (Preclinical/Research) |
| SGT-501 | Catecholaminergic polymorphic ventricular tachycardia (CPVT) | Not Specified (Preclinical/Research) |
| SGT-601 | TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases | Not Specified (Preclinical/Research) |
Leadership Team at Solid Biosciences
BC
Bo Cumbo
President and CEO
KT
Kevin Tan
Chief Financial Officer
TH
Ty Howton
Chief Operating Officer
DG
Dr. Gabriel Brooks, M.D.
Chief Medical Officer
PH
Paul Herzich
Chief Technology Officer
SK
Shuli Kulak, M.D.
Head of Corporate Strategy and Business Development